三新两化

Search documents
“三新两化”战略顺利推进 九州通2025上半年营利双增
Jing Ji Guan Cha Wang· 2025-08-26 12:50
其中,在新产品战略方面,九州通发挥全集团相关业务组织整合资源优势,已形成以CSO为核心的新产 品业务组织矩阵,采用独家代理、股权合作、买断权利、自主研发等多种形式,获取兼具临床价值和市 场空间,并且适合于公司的新产品。报告期内,公司新增引进药品新品61个,总代品牌推广业务(含药 品及医疗器械)销售收入达95.91亿元。 新零售战略方面,九州通以好药师"万店加盟"为核心,形成包含B2C电商总代总销、药九九B2B电商平 台、零售电商等业务矩阵,打造触及C端客户的全方位、全场景的"线上线下(300959)一体化"新零售 服务体系。上半年,面向C端的新零售业务实现销售收入14.93亿元(含B2C电商总代总销等业务),同 比增长2.52%。 截至2025年6月底,好药师直营及加盟药店门店总数达31,535家,预计2025年末门店数将超33,500家。与 此同时,好药师开始注重经营质量的提升,积极拓展合作供应商,全国累计拥有超800家品牌供应商为 加盟店提供强力品牌品种保障,已引进定制品种76个,集采战略合作KA政策品种累计达625个。上半年 公司向加盟药店销售收入达34.18亿元,同比增长41.30%。 8月26日晚间 ...
九州通主体信用评级上调为AAA
Jing Ji Guan Cha Bao· 2025-08-26 10:25
(原标题:九州通主体信用评级上调为AAA) 8月26日,九州通(600998.SH)对外公告,公司日前收到信用评级机构中诚信国际信用评级有限责任 公司(以下简称"中诚信")对公司主体信用状况的评级结果,评定公司主体信用等级为AAA,评级展 望为"稳定"。 公告披露,中诚信向九州通出具了《2025年度九州通医药集团股份有限公司信用评级报告》(编号: CCXI-20253191M-01),在对公司生产经营状况、政策环境及相关行业情况进行综合分析与评估的基础 上,评定上调公司主体信用等级为AAA,评级展望为"稳定",公司前次主体信用评级结果为AA+。 对于此次主体信用评级上调的原因,九州通在公告中表示,近年来,公司专注于医药大健康主业经营, 新产品、新零售、新医疗、数字化和不动产证券化("三新两化")战略进展顺利,可持续发展能力不断 增强;公司在内部管理、供应链体系、经营模式等方面坚持创新,已实现"数字化、平台化、互联网 化"的大健康产业服务转型升级,建立了"全品类采购、全渠道覆盖和全场景服务"的"千亿级"医药供应 链服务平台,公司核心竞争力持续提升;同时,公司实施高效稳健的数字化财务管理模式,同步构建严 谨完善的 ...
以“三新两化”战略绘就大健康产业新蓝图
Zhong Guo Zheng Quan Bao· 2025-07-13 20:52
Core Viewpoint - The company is transforming its development momentum through the "Three New and Two Transformations" strategy, focusing on digital transformation, new retail, and new medical services to become the most professional health service provider in China and achieve its goal of becoming a century-old enterprise [1][7]. Digital Empowerment - The company has evolved from a grassroots pharmaceutical wholesaler to a technology-driven comprehensive service provider in the pharmaceutical industry, with a clear strategic path and implementation results in its digital transformation [1][2]. - The digital transformation includes collaboration across business, management, and logistics, with a focus on reducing costs and increasing efficiency [2][3]. - The company has achieved a significant reduction in logistics errors, with an error rate controlled at one in a million, enhancing both efficiency and quality [2]. Strategic Focus - The "Three New" strategy addresses the long-standing "two disconnections" in the industry by enhancing control over upstream products and establishing a new retail network for downstream channels [2][5]. - The company aims for new product-related sales to account for 20% of total revenue and 50% of gross profit in the next three years [3][5]. Medical Aesthetics Business - The company is accelerating its layout in the medical aesthetics sector, which has shown rapid growth, increasing from several million to several billion in scale [5][6]. - The medical aesthetics market is seen as a key profit growth point, driven by the aging population and rising consumer demand for beauty services [5][6]. Talent Strategy - The company has shifted its talent acquisition strategy, significantly increasing the recruitment of external senior talent to meet the demands of its strategic transformation [6][7]. - In 2023, the company introduced a "Three Transformations Talent Strategy," aiming to recruit over 300 senior talents annually [6]. Financial Performance - The company's sales revenue has grown from 21.185 billion in 2010 to 151.81 billion in 2024, with a compound annual growth rate of 15.10% [6]. - The net profit attributable to the parent company increased from 360 million in 2010 to 2.507 billion in 2024, with a compound annual growth rate of 14.88% [6].
九州通(600998):经营韧性强 看好“三新两化”持续兑现
Xin Lang Cai Jing· 2025-05-07 08:34
Performance - In 2024, the company achieved total operating revenue of 151.81 billion, a year-on-year increase of 1.11%; net profit attributable to shareholders was 2.51 billion, up 15.33%; and net profit excluding non-recurring items was 1.81 billion, down 7.47% [1] - In Q1 2025, total operating revenue reached 42.02 billion, a year-on-year increase of 3.82%; net profit attributable to shareholders was 970 million, a significant increase of 80.38%; and net profit excluding non-recurring items was 507 million, down 2.76% [1] Growth Potential - The company successfully launched its REITs, marking a new chapter in light asset operations, with the public offering of pharmaceutical warehousing logistics REITs raising 1.16 billion on February 27, 2025 [2] - The CSO business continued to grow, achieving sales revenue of 19.27 billion, with pharmaceutical CSO revenue at 10.77 billion, a year-on-year increase of 19.59% after adjusting for high base effects [2] New Retail and New Medical - The "Good Pharmacist" franchise rapidly expanded, reaching 29,331 stores by the end of March 2025, with sales to franchise pharmacies amounting to 5.39 billion, a year-on-year increase of 54.94% [3] - The "Nine Medical Clinics" membership stores reached 1,377 by the end of March 2025, utilizing AI-assisted diagnostic platforms to empower grassroots medical institutions [3] Profitability - The overall gross margin for 2024 was 7.80%, a decrease of 0.27 percentage points, while Q1 gross margin was 7.33%, an increase of 0.13 percentage points [4] - The net profit margin attributable to shareholders for 2024 was 1.65%, an increase of approximately 0.21 percentage points, with Q1 2025 net profit margin at 2.31%, a significant increase of 0.98 percentage points [4] Operating Quality - The net cash flow from operating activities in 2024 was 3.08 billion, a year-on-year decrease of 35.07%, primarily due to increased procurement payments from strategic cooperation with core suppliers [5] - By Q1 2025, the company's operating cash flow remained stable year-on-year, with slight increases in accounts receivable turnover days and inventory turnover days [5] Profit Forecast and Valuation - Revenue projections for 2025-2027 are 163.29 billion, 176.46 billion, and 190.08 billion, with corresponding growth rates of 7.56%, 8.06%, and 7.72% [6] - Expected net profits attributable to shareholders for the same period are 2.84 billion, 3.18 billion, and 3.54 billion, with year-on-year growth rates of 13.13%, 12.08%, and 11.21% [6]
九州通一季度净利大增80.38% “三新两化”转型成效显著
Chang Jiang Shang Bao· 2025-05-06 23:31
Core Viewpoint - The strategic transformation of the company, driven by the "Three New and Two Digital" strategy, has led to steady growth in performance, with significant increases in revenue and profit in 2024 and Q1 2025 [2][3][5]. Financial Performance - In 2024, the company achieved a total revenue of 151.81 billion yuan, a year-on-year increase of 1.11%, and a net profit attributable to shareholders of 2.507 billion yuan, up 15.33% [3][5]. - The net cash flow from operating activities turned positive at 3.083 billion yuan [3]. - For Q1 2025, the company reported revenue of 42.016 billion yuan, a growth of 3.82%, and a net profit of approximately 970 million yuan, an increase of 80.38% [4][5]. Business Segments - The core pharmaceutical distribution business showed stable growth, while emerging sectors like industrial self-production, OEM, traditional Chinese medicine, and digital logistics grew rapidly, each with a growth rate around 20% [3][4]. - The industrial self-production and OEM segment generated sales of 5.92 billion yuan, up 26.92%, with a gross margin of 42.48% [3]. - The traditional Chinese medicine segment achieved sales of 4.962 billion yuan, a growth of 18.14%, supported by a blockchain-based quality traceability platform [4]. Strategic Initiatives - The company is focusing on new product strategies, with sales from the pharmaceutical agency brand promotion business reaching 19.267 billion yuan, introducing 2,247 drug and device specifications [5][6]. - The new retail strategy has established over 29,000 franchise pharmacies, with B2C e-commerce sales reaching 980 million yuan and over 35 million end-users [5][6]. - The new medical strategy includes the development of an AI-assisted diagnostic platform in collaboration with Tencent Cloud, enhancing service efficiency for clinics and grassroots medical institutions [6]. Digital Transformation - The company invested 346 million yuan in digital and intelligent technology innovation, with 47 digital transformation projects implemented, 45 of which have been successfully launched [6]. - The logistics segment achieved revenue of 1.064 billion yuan, a growth of 25.32%, with a gross profit of 236 million yuan, up 17.08% [4]. Real Estate Investment Trusts (REITs) - The company completed the issuance of public REITs for its pharmaceutical warehousing and logistics, raising 1.158 billion yuan, marking a significant step towards asset-light transformation [7]. - The public REITs issuance saw a subscription multiple of 1,192 times, setting a historical record for public REITs [7].
九州通2024年业绩稳中有进,一季度净利大增80.38%
Quan Jing Wang· 2025-04-29 03:05
Core Insights - The company reported stable growth in its 2024 annual report and Q1 2025 results, with 2024 revenue reaching 151.81 billion yuan and net profit attributable to shareholders at 2.507 billion yuan, reflecting a year-on-year increase of 39.88% [1][4] - The company is focusing on high-quality development and strategic transformation, emphasizing new products, new retail, new medical services, digitalization, and real estate securitization [1][6] Financial Performance - In 2024, the company achieved a revenue of 151.81 billion yuan, with a net profit of 2.507 billion yuan, and a non-recurring net profit of 1.814 billion yuan, showing a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% [1][4] - For Q1 2025, the company reported a revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, marking an 80.38% increase compared to the same period last year [1] Strategic Initiatives - The company is implementing a comprehensive service model that integrates pharmaceutical distribution, logistics, and product promotion, transitioning from traditional distribution to digital and platform-based services [4] - The company has established a full industry chain layout for traditional Chinese medicine, achieving a sales revenue of 4.962 billion yuan, with a year-on-year growth of 18.14% [5] - The company is actively developing digital logistics and supply chain solutions, with this segment generating 1.064 billion yuan in revenue, a 25.32% increase year-on-year [5] Social Responsibility and Shareholder Returns - In 2024, the company donated nearly 18.21 million yuan for public welfare, focusing on energy conservation, rural revitalization, and disaster relief [2][11] - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares, totaling 999.7 million yuan, which, along with a stock buyback of 268 million yuan, amounts to 1.265 billion yuan, representing 50.47% of the annual net profit [2][12] Talent Acquisition and Future Outlook - The company has introduced 264 high-end professionals to support its strategic transformation, with a significant increase in investment for talent acquisition [12][13] - Looking ahead, 2025 is seen as a crucial year for the company to finalize its three-year strategic plan and continue advancing its transformation initiatives [13]
“三新两化”转型显效 九州通2024年营收1518亿元
Jing Ji Guan Cha Bao· 2025-04-28 14:39
Core Viewpoint - The company, Jiuzhoutong, reported a revenue of 151.81 billion yuan for 2024, with a net profit of 2.51 billion yuan, indicating a strategic transformation focusing on high-quality development through the "Three New and Two Transformations" strategy [2][5]. Financial Performance - In 2024, Jiuzhoutong achieved a revenue of 1518.10 billion yuan, with a year-on-year growth of 2.58% after adjusting for seasonal factors. The net profit attributable to shareholders increased by 39.88% to 2.51 billion yuan, while the net profit excluding non-recurring items rose by 14.89% to 1.81 billion yuan [2][3]. - For Q1 2025, the company reported a revenue of 420.16 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% growth compared to the same period last year [2]. Strategic Transformation - Jiuzhoutong is focusing on a strategic transformation that includes new products, new retail, new medical services, digitalization, and real estate securitization, collectively referred to as "Three New and Two Transformations" [2][5]. - The company is enhancing its core competitiveness in product introduction, C-end channel construction, digital technology development, and asset operation models [5][6]. Core Business Development - The core pharmaceutical distribution business is experiencing stable growth, with emerging sectors such as industrial self-production, OEM, traditional Chinese medicine, and digital logistics showing growth rates around 20% [3][4]. - The industrial self-production and OEM segment achieved sales of 5.92 billion yuan, a 26.92% increase, while the traditional Chinese medicine segment reported sales of 22.86 billion yuan, up 21.45% [3]. Digital and Logistics Innovations - Jiuzhoutong has established a complete industry chain for traditional Chinese medicine, achieving sales of 4.96 billion yuan, an 18.14% increase, and has developed digital systems for quality tracking and smart manufacturing [4]. - The digital logistics and supply chain solutions segment generated revenue of 1.06 billion yuan, a 25.32% increase, with a gross profit of 236 million yuan, up 17.08% [4]. Future Outlook - The company views 2025 as a critical year for the implementation of its three-year strategic plan and aims to continue advancing the "Three New and Two Transformations" strategy while focusing on talent acquisition [7].